Molecular diagnostics company oncgnostics GmbH closes Series A financing round for CE mark and market entry of its cervical cancer diagnostics test GynTect®
oncgnostics develops, based on proprietary epigenetic biomarkers molecular tests for reliable cancer diagnostics. With t…